J. Taieb elaborates clinical perspective of new players in mCRC therapeutic arena. Molecular analysis from the RECOURSE study, showed that TAS-102 is equally effective in KRAS mutant and wild-type tumours. Conclusions for BRAF subset cannot be drawn due to small numbers. TAS-102 reverse 5-FU activity and it is well tolerated in heavily pretreated patients. Further, he elaborates the QoL data from the RAISE study of FOLFIRI plus ramucirumab, a Monoclonal antibody directed against VEGFR2 after first-line therapy with bevacizumab in mCRC.

Oncology Meeting Resources

Major Sponsors

AstraZeneca Janssen Lilly Oncology

Main Sponsors

Amgen Astellas Bayer Healthcare Boehringer Ingelheim Daiichi Sankyo Genomic Health Inc. Roche